



STATE OF TENNESSEE


2024 Episodes of Care Results

Results of Episodes of Care Program

2024 *Estimated Savings**: **\$66.1 million.**

Quality metrics **improved** or maintained for most episodes in 2024.

Estimated Annual Savings* from Episodes of Care Program, 2015-2024



*Estimated savings based on 3% annual medical inflation rate.


Results of Episodes of Care Program

32.9% of providers received net gain-sharing incentive payments*.

6.8% of providers made net risk-sharing incentive payments*.

2024 Provider Net Incentive Payments

Individual Episodes	802,037
Provider Quarterbacks	2,205
Quarterbacks with Net Gain-Sharing*	726
Quarterbacks with Net Risk-Sharing*	150



* Some providers had both gain-sharing and risk-sharing payments in different episode types or with different MCOs. These results report the providers' net incentive payment outcomes.



SAVINGS RESULTS

2024 Episodes Savings

Estimated savings for 2024 is approximately **\$66.1 million** due to Episodes' risk-adjusted cost being less than projected medical trend of a 3% annual increase

Episode Type	Projected	Actual	Estimated Savings per Episode	Percent Savings per Episode	Number of Valid Episodes	Total Estimated Savings
Total	-	-	-	-	802,037	\$66,070,906
Acute Gastroenteritis	\$685	\$678	\$8	1.1%	17,250	\$135,425
Acute Kidney & Ureter Stones	\$1,068	\$906	\$162	15.2%	1,534	\$248,807
Acute PCI	\$11,533	\$10,513	\$1,021	8.8%	146	\$149,008
Acute Seizure	\$1,692	\$1,623	\$69	4.1%	4,394	\$301,853
ADHD	\$1,538	\$1,175	\$363	23.6%	26,665	\$9,674,865
Appendectomy	\$5,936	\$5,612	\$324	5.5%	1,098	\$355,913
Asthma Acute Exacerbation	\$1,537	\$943	\$594	38.6%	7,801	\$4,630,191
Back/Neck Pain	\$453	\$430	\$23	5.0%	29,681	\$668,949
Bariatric Surgery	\$9,635	\$6,060	\$3,575	37.1%	484	\$1,730,321
Breast Biopsy	\$2,067	\$1,670	\$396	19.2%	688	\$272,728
Bronchiolitis	\$749	\$755	-\$6	-0.8%	3,784	-\$22,809
CHF Acute Exacerbation	\$7,066	\$6,530	\$537	7.6%	1,407	\$755,306
Cholecystectomy	\$5,723	\$4,923	\$800	14.0%	1,536	\$1,229,534
Colonoscopy	\$1,368	\$1,084	\$284	20.7%	2,433	\$690,018
Colposcopy	\$430	\$478	-\$48	-11.1%	2,427	-\$115,384
COPD	\$2,939	\$2,116	\$824	28.0%	1,557	\$1,282,338
Cystourethroscopy	\$1,012	\$1,251	-\$239	-23.6%	1,447	-\$345,924
Diabetes Acute Exacerbation	\$6,520	\$5,784	\$736	11.3%	861	\$634,018
EGD	\$1,489	\$1,264	\$225	15.1%	5,007	\$1,128,030
Gastrointestinal Hemorrhage	\$4,384	\$2,714	\$1,670	38.1%	886	\$1,479,493
GI Obstruction	\$10,293	\$6,559	\$3,733	36.3%	415	\$1,549,388
Hernia Repair	\$5,004	\$3,943	\$1,061	21.2%	1,288	\$1,366,567
Hysterectomy	\$5,906	\$5,300	\$606	10.3%	783	\$474,532

2024 Episodes Savings

Estimated savings for 2024 is approximately **\$66.1 million** due to Episodes' risk-adjusted cost being less than projected medical trend of a 3% annual increase

Episode Type	Projected	Actual	Estimated Savings per Episode	Percent Saving per Episode	Number of Valid Episodes	Total Estimated Savings
Total	-	-	-	-	802,037	\$66,070,906
Knee Arthroscopy	\$3,674	\$3,715	-\$41	-1.1%	663	-\$26,988
Non-Operative Ankle Injury	\$368	\$331	\$37	10.0%	13,678	\$501,040
Non-Operative Knee Injury	\$460	\$394	\$67	14.5%	7,318	\$489,204
Non-Operative Shoulder Injury	\$393	\$340	\$53	13.6%	5,929	\$316,199
Non-Operative Wrist Injury	\$419	\$337	\$82	19.6%	8,229	\$675,965
ODD	\$1,629	\$996	\$633	38.8%	1,723	\$1,090,386
Otitis Media	\$188	\$152	\$36	19.1%	137,177	\$4,921,117
Pancreatitis	\$7,197	\$6,609	\$588	8.2%	635	\$373,645
Pediatric Pneumonia	\$1,047	\$952	\$95	9.1%	5,268	\$502,501
Perinatal	\$8,735	\$7,760	\$975	11.2%	15,586	\$15,193,906
Pneumonia	\$1,505	\$1,417	\$88	5.9%	2,317	\$204,118
Respiratory Infection	\$149	\$144	\$5	3.4%	399,215	\$1,990,392
Skin and Soft Tissue Infection	\$261	\$209	\$52	20.0%	39,558	\$2,064,858
Spinal Decompression w/o Fusion	\$6,481	\$5,505	\$976	15.1%	160	\$156,220
Spinal Fusion	\$24,535	\$17,118	\$7,417	30.2%	330	\$2,447,536
Syncope	\$767	\$487	\$279	36.4%	7,055	\$1,971,183
Tonsillectomy	\$3,154	\$2,628	\$526	16.7%	7,469	\$3,930,995
Total Joint Replacement	\$15,813	\$10,674	\$5,139	32.5%	169	\$868,520
UTI - Inpatient	\$5,020	\$6,003	-\$984	-19.6%	1,373	-\$1,350,402
UTI - Outpatient	\$186	\$143	\$43	23.0%	34,613	\$1,477,344



QUALITY PERFORMANCE

Episode gain-sharing Quality Metrics – Wave 1

Wave 1 Episodes*	CY 2020	CY 2021	CY 2022	CY 2023	CY 2024	Target Performance
Perinatal (15,586 valid episodes)						
1. HIV Screening (≥ 90%)	91.5%	87.2%	86.6%	90.1%	94.7%	<i>Higher is better</i>
2. Hepatitis C Screening (≥ 90%)**	-	46.5%	56.5%	71.9%	82.3%	<i>Higher is better</i>
3. Primary C-Section Rate (≤ 25%)***	16.5%	16.7%	12.4%	12.4%	11.6%	<i>Lower is better</i>
Acute Asthma Exacerbation (7,801 valid episodes)						
1. Follow-up Visit with Physician (≥ 30%)	27.4%	30.6%	33.3%	31.9%	33.0%	<i>Higher is better</i>
2. Patient on Appropriate Medication (≥ 60%)	62.8%	61.5%	66.8%	65.8%	64.2%	<i>Higher is better</i>
Total Joint Replacement (169 valid episodes)						
1. Admission Within the Post-Trigger Window 1 (≥ 10%)	3.1%	0.7%	0.8%	1.7%	1.2%	<i>Lower is better</i>

*Valid episodes in 2024 performance period across all three MCOs.

**This quality metric was added in 2021. Information is not available for years before 2021.

***In 2022, the design of this quality metric was changed to align with the Agency for Healthcare Research and Quality (AHRQ) definition of primary C-section delivery rate.



Episode gain-sharing Quality Metrics – Wave 2

Wave 2 Episodes*	CY 2020	CY 2021	CY 2022	CY 2023	CY 2024	Target Performance
Cholecystectomy (1,536 valid episodes)						
1. Hospitalization in Post-Trigger Window (\leq 10%)	0.3%	0.3%	0.1%	0.3%	0.3%	<i>Lower is better</i>
COPD (1,557 valid episodes)						
1. Follow-up Care Within Post-Trigger Window (\geq 45%)	44.6%	44.6%	46.1%	45.6%	48.4%	<i>Higher is better</i>
Acute PCI (146 valid episodes)						
1. Hospitalization in Post-Trigger Window (\leq 10%)	0.0%	0.7%	1.8%	0.9%	2.1%	<i>Lower is better</i>
Non-acute PCI (42 valid episodes)						
1. Hospitalization in Post-Trigger Window (\leq 10%)	0.0%	0.0%	0.0%	0.0%	0.0%	<i>Lower is better</i>

Note: There are no quality metrics tied to gain-sharing for the colonoscopy episode.

*Valid episodes in 2024 performance period across all three MCOs



Episode gain-sharing Quality Metrics – Wave 3

Wave 3 Episodes*	CY 2020	CY 2021	CY 2022	CY 2023	CY 2024	Target Performance
GI Hemorrhage (886 valid episodes)						
1. Follow-up Care Within Post-Trigger Window (≥ 45%)	47.7%	47.6%	47.0%	47.4%	45.4%	Higher is better
Pneumonia (2,317 valid episodes)						
1. Follow-up Care Within Post-Trigger Window (≥ 30%)	29.3%	27.9%	28.3%	29.3%	28.6%	Higher is better
UTI-Inpatient (1,373 valid episodes)						
1. Follow-up Care Within Post-Trigger Window (≥ 40%)	43.8%	41.5%	43.7%	42.3%	45.7%	Higher is better
UTI-Outpatient (34,613 valid episodes)						
1. Admission Within the Trigger Window for ED Triggered Episodes (≤ 5%)**	7.3%	6.7%	5.9%	5.8%	8.4%	Lower is better
2. Admission Within the Trigger Window for Non-ED Triggered Episodes (≤ 5%)**	0.9%	0.7%	0.6%	0.7%	0.7%	Lower is better
Respiratory Infection (399,215 valid episodes)						
1. ED Visit Within the Post-Trigger Window (≤ 10%)	2.2%	1.7%	1.9%	1.9%	1.9%	Lower is better
EGD (5,007 valid episodes)						
1. ED Visit Within the Post-Trigger Window (≤ 10%)	4.0%	3.4%	3.2%	3.4%	3.2%	Lower is better

*Valid episodes in 2024 performance period across all three MCOs

**This gain-sharing quality metric applies to a subpopulation. As a result, the rate is not indicative of performance for all valid episodes.



Episode gain-sharing Quality Metrics – Wave 4

Wave 4 Episodes*	CY 2020	CY 2021	CY 2022	CY 2023	CY 2024	Target Performance
Bariatric Surgery (484 valid episodes)						
1. Follow-up Care Within Post-Trigger Window (≥ 30%)	42.2%	45.0%	44.8%	49.3%	47.1%	Higher is better
CHF Acute Exacerbation (1,407 valid episodes)						
1. Follow-up Care Within Post-Trigger Window (≥ 60%)	54.6%	54.1%	54.8%	55.4%	54.2%	Higher is better
ODD (1,723 valid episodes)						
1. Minimum Care Requirement (≥ 30%)	34.4%	33.8%	30.6%	33.7%	32.7%	Higher is better
CABG (50 valid episodes)						
1. Follow-up Care Within Post-Trigger Window (≥ 90%)	88.3%	74.4%	70.4%	74.3%	80.0%	Higher is better
Valve Repair and Replacement (18 valid episodes)						
1. Follow-up Care Within Post-Trigger Window (≥ 90%)	63.6%	40.0%	71.0%	74.0%	66.7%	Higher is better
ADHD (26,665 valid episodes)						
1. Minimum Care Requirement (≥ 70%)	74.0%	76.2%	76.7%	76.5%	76.5%	Higher is better
2. Utilization of Therapy for Members Aged 4 and 5 Years (1 visit)**	1.24	1.04	1.04	0.88	0.86	Higher is better

*Valid episodes in 2024 performance period across all three MCOs

**This gain-sharing quality metric applies to a subpopulation. As a result, the rate is not indicative of performance for all valid episodes.



Episode gain-sharing Quality Metrics – Wave 5

Wave 5 Episodes*	CY 2020	CY 2021	CY 2022	CY 2023	CY 2024	Target Performance
Breast Biopsy (688 valid episodes)						
1. Appropriate Diagnostic Workup Rate (≥ 90%)	83.5%	90.6%	92.4%	93.9%	91.0%	<i>Higher is better</i>
2. Core Needle Biopsy Rate (≥ 85%)**	92.0%	91.3%	83.1%	87.1%	84.4%	<i>Higher is better</i>
Tonsillectomy (7,469 valid episodes)						
1. Bleeding Up to Two Days Following the Procedure (≤ 5%)	0.7%	0.9%	0.02%	0.1%	0.1%	<i>Lower is better</i>
Otitis Media (137,177 valid episodes)						
1. Otitis Media with Effusion (OME) Episodes without Antibiotics Filled (≥ 25%)**	35.2%	29.5%	27.1%	29.6%	32.8%	<i>Higher is better</i>
2. Non-OME Episodes with Amoxicillin (≥ 60%)**	63.7%	66.0%	65.8%	66.6%	66.7%	<i>Higher is better</i>

*Valid episodes in 2024 performance period across all three MCOs

** This gain-sharing quality metric applies to a subpopulation. As a result, the rate is not indicative of performance for all valid episodes.



Episode gain-sharing Quality Metrics – Wave 6

Wave 6 Episodes*	CY 2020	CY 2021	CY 2022	CY 2023	CY 2024	Target Performance
Skin and Soft Tissue Infection (39,558 valid episodes)						
1. Bacterial Cultures when Incision and Drainage Performed (≥ 50%)**	42.4%	43.3%	39.1%	37.3%	39.6%	Higher is better
2. SSTI Episodes with a First Line Antibiotic (≥ 85%)**	97.6%	97.8%	97.6%	97.6%	97.8%	Higher is better
HIV (1,134 valid episodes)						
1. Periodic anti-retroviral therapy (ART) refill (≥ 85%)	75.8%	69.8%	75.8%	80.0%	80.8%	Higher is better
Diabetes Acute Exacerbation (861 valid episodes)						
1. Follow-up care in the first 30 days of the post-trigger window (≥ 30%)***	27.9%	28.3%	46.0%	47.8%	52.8%	Higher is better
Pancreatitis (635 valid episodes)						
1. Follow-up care in the first 14 days of the post-trigger window (≥ 35%)	32.9%	30.0%	47.4%	46.0%	48.2%	Higher is better

* Valid episodes in 2024 performance period across all three MCOs

** This gain-sharing quality metric applies to a subpopulation. As a result, the rate is not indicative of performance for all valid episodes.

*** In 2022, the time window for this quality metric changed from 14 days to 30 days.



Episode gain-sharing Quality Metrics – Wave 7

Wave 7 Episodes*	CY 2020	CY 2021	CY 2022	CY 2023	CY 2024	Target Performance
Spinal Fusion (330 valid episodes)						
1. Difference in Average MED/Day (≤ 8.0)	2.17	5.0**	0.81	0.84	0.86	Lower is better
Spinal Decompression (160 valid episodes)						
1. Difference in Average MED/Day (≤ 1.0)	1.40	-1.10	0.86	0.87	0.86	Lower is better
Femur/Pelvic Fracture (176 valid episodes)						
1. Related follow-up care ($\geq 30\%$)	7.0%	5.1%	6.8%	10.2%	6.3%	Higher is better
2. Difference in Average MED/Day (≤ 8.0)	10.0	-7.44	0.89	0.82	0.87	Lower is better
Knee Arthroscopy (663 valid episodes)						
1. Difference in Average MED/Day (≤ 1.0)	-0.47	0.30	0.92	0.93	0.93	Lower is better
Non-operative Ankle Injury (13,678 valid episodes)						
1. Difference in Average MED/Day (≤ 1.0)	0.87	0.09	0.94	0.95	0.96	Lower is better
Non-operative Wrist Injury (8,229 valid episodes)						
1. Difference in Average MED/Day (≤ 1.0)	0.19	0.96	0.92	0.94	0.95	Lower is better
Non-operative Shoulder Injury (5,925 valid episodes)						
1. Difference in Average MED/Day (≤ 1.0)	1.37	0.75	0.88	0.89	0.90	Lower is better
Non-operative Knee Injury (7,318 valid episodes)						
1. Difference in Average MED/Day (≤ 1.0)	1.01	0.76	0.92	0.93	0.93	Lower is better
Back/Neck Pain (29,681 valid episodes)						
1. Difference in Average MED/Day (≤ 1.0)	4.58	3.40	0.72	0.76	0.77	Lower is better

*Valid episodes in 2024 performance period across all three MCOs

**This quality metric is based on a formula related to opioid prescriptions. The increase for these metrics was driven by a few episode outliers that are being investigated and addressed by the Managed Care Organizations and aligned with TennCare’s overall opioid strategy. For more information on TennCare’s Opioid Strategy, please visit the following website - <https://www.tn.gov/tenncare/tenncare-s-opioid-strategy.html>



Episode gain-sharing Quality Metrics – Wave 8

Wave 8 Episodes*	CY 2020	CY 2021	CY 2022	CY 2023	CY 2024	Target Performance
Acute Seizure (4,394 valid episodes)						
1. Brain MRI Utilization in Focal Epilepsy (≥ 10%)**	18.3%	16.1%	14.9%	15.0%	17.8%	Higher is better
2. Prolonged EEG Monitoring Utilization in Newly Diagnosed Seizure (≥ 10%)**	2.8%	2.2%	3.7%	8.8%	10.5%	Higher is better
Syncope (7,055 valid episodes)						
1. Carotid Ultrasound Imaging in Adults (≤ 10%)**	3.7%	3.4%	3.4%	3.1%	2.5%	Lower is better
Bronchiolitis (3,784 valid episodes)						
1. Related Admission during the Post-Trigger Window (≤ 10%)	0.8%	0.7%	0.8%	0.8%	0.8%	Lower is better
2. Utilization of Bronchodilators (≤ 30%)	13.0%	14.6%	17.9%	16.8%	18.0%	Lower is better
3. Utilization of Steroids (≤ 50%)	20.4%	22.7%	27.5%	26.6%	28.4%	Lower is better
Pediatric Pneumonia (5,268 valid episodes)						
1. Related Admission during the Post-Trigger Window (≤ 10%)	0.6%	0.9%	0.7%	0.9%	0.9%	Lower is better
2. Utilization of Macrolides in Patients Under 6 Years Old (≤ 30%) **	18.2%	17.0%	14.4%	13.8%	38.1%	Lower is better
3. Utilization of Narrow Spectrum Antibiotics (≥ 50%)	56.7%	61.8%	65.0%	66.8%	55.6%	Higher is better

*Valid episodes in 2024 performance period across all three MCOs

** This gain-sharing quality metric applies to a subpopulation. As a result, the rate is not indicative of performance for all valid episodes.



Episode gain-sharing Quality Metrics – Wave 8

Wave 8 Episodes*	CY 2020	CY 2021	CY 2022	CY 2023	CY 2024	Target Performance
Colposcopy (2,427 valid episodes)						
1. LEEP Utilization Under 26 Years Old With No Evidence of High-Grade Dysplasia ($\leq 10\%$)**	1.9%	1.6%	3.1%	1.4%	2.4%	Lower is better
2. LEEP Util. w/ Low-Grade Dysplasia ($\leq 10\%$)**	11.0%	13.2%	9.8%	8.5%	8.0%	Lower is better
Hysterectomy (783 valid episodes)						
1. Alternative Treatments ($\geq 20\%$)***	43.7%	45.8%	65.3%	61.2%	61.3%	Higher is better
2. Related Follow-up Care ($\geq 10\%$)	22.2%	33.8%	34.4%	39.5%	31.7%	Higher is better
GI Obstruction (415 valid episodes)						
1. Related Follow-up Care ($\geq 20\%$)	35.6%	34.0%	36.3%	37.5%	39.3%	Higher is better
2. Difference in Average MED/Day (≤ 1.0)	3.53	4.08	0.89	0.90	0.87	Lower is better
Appendectomy (1,098 valid episodes)						
1. Abdominopelvic CT Scans in Children ($\leq 50\%$)**	39.2%	36.7%	43.1%	37.9%	37.3%	Lower is better
1. Difference in Average MED/Day (≤ 1.0)	1.55	-0.06	0.97	0.98	0.98	Lower is better
Hernia Repair (1,288 valid episodes)						
1. Difference in Average MED/Day (≤ 1.0)	1.39	-1.11	0.93	0.96	0.96	Lower is better
Acute Gastroenteritis (17,250 valid episodes)						
1. Abdominopelvic CT/MRI in Adults ($\leq 40\%$)**	45.3%	47.5%	48.9%	51.9%	51.3%	Higher is better
2. Abdominopelvic CT/MRI in Children ($\leq 40\%$)**	6.8%	6.2%	6.0%	7.2%	7.3%	Higher is better
3. Antibiotics Utilization ($\leq 30\%$)	24.1%	21.8%	20.7%	23.9%	22.7%	Higher is better



*Valid episodes in 2024 performance period across all three MCOs
 ** This gain-sharing quality metric applies to a subpopulation. As a result, the rate is not indicative of performance for all valid episodes.
 ***In 2022, the look-back window for this quality metric was changed from 180 days to 960 days.

Episode gain-sharing Quality Metrics – Wave 9

Wave 9 Episodes*	CY 2020	CY 2021	CY 2022	CY 2023	CY 2024	Target Performance
Cystourethroscopy (1,447 valid episodes)						
1. Difference in Average MED/Day (≤ 1.0)	-0.22	0.90	0.82	0.84	0.86	<i>Lower is better</i>
2. Related ED Visit (≤ 10%)	5.6%	3.4%	4.6%	5.6%	6.6%	<i>Lower is better</i>
3. Repeat cystourethroscopy (≤ 5%)	2.6%	4.3%	3.6%	6.5%	5.9%	<i>Lower is better</i>
Acute Kidney and Ureter Stones (1,534 valid episodes)						
1. Difference in Average MED/Day (≤ 3.0)	3.16	1.03	0.89	0.89	0.89	<i>Lower is better</i>
2. Related ED Visit (≤ 15%)	16.0%	15.8%	14.1%	14.5%	13.8%	<i>Lower is better</i>



*Valid episodes in 2024 performance period across all three MCOs